Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Mary E. Kos"'
Autor:
Vinicius Ernani, Rahat Jahan, Lynette M. Smith, Alissa S. Marr, Sarah E. Kimbrough, Mary E. Kos, Jolene Tijerina, Shannon Pivovar, Imayavaramban Lakshmanan, Marsha Ketcham, Sanchita Rauth, Kavita Mallya, Mohd W Nasser, Maneesh Jain, Anne Kessinger, Surinder K. Batra, Apar Kishor Ganti
Publikováno v:
Cancer Treatment and Research Communications, Vol 22, Iss , Pp 100162- (2020)
Background: Relapsed/refractory small cell lung cancer (SCLC) has a poor prognosis, with no good options. We evaluated a novel combination of topotecan and doxorubicin, providing sequential topoisomerase I and II inhibition, in this setting. Material
Externí odkaz:
https://doaj.org/article/09a09fb0c2ae471585c4a6b162714dc9
Autor:
Surinder K. Batra, Anne Kessinger, Vinicius Ernani, Imayavaramban Lakshmanan, Jolene Tijerina, Maneesh Jain, Mohd W. Nasser, Lynette M. Smith, Rahat Jahan, Sarah E. Kimbrough, Shannon Pivovar, Mary E. Kos, Kavita Mallya, Apar Kishor Ganti, Sanchita Rauth, Alissa S. Marr, Marsha A. Ketcham
Publikováno v:
Cancer Treatment and Research Communications, Vol 22, Iss, Pp 100162-(2020)
Cancer Treat Res Commun
Cancer Treat Res Commun
Background Relapsed/refractory small cell lung cancer (SCLC) has a poor prognosis, with no good options. We evaluated a novel combination of topotecan and doxorubicin, providing sequential topoisomerase I and II inhibition, in this setting. Materials
Autor:
Marsha A. Ketcham, Alissa S. Marr, Anne Kessinger, Mary M. Huerter, Addison Tolentino, Karin Swenson, Holly DeSpiegelaere, Jane L. Meza, M. Sitki Copur, Apar Kishor Ganti, Susan Kruse, Mary E. Kos, Sarah E. Radniecki
Publikováno v:
Journal of Geriatric Oncology. 8:18-22
Objective Platinum-based doublet chemotherapy is the standard for most patients with advanced non-small cell lung cancer (NSCLC). Toxicity concerns limit chemotherapy for patients over 70 years. Vinorelbine and paclitaxel are effective as single agen
Publikováno v:
Cancer. 121:3862-3868
Pralatrexate (PDX) is an inhibitor of dihydrofolate reductase that was rationally designed to improve cellular uptake and retention of the drug. Preclinical data have shown synergy with the sequential administration of a dihydrofolate reductase inhib
Publikováno v:
Cancer. 121(21)
Pralatrexate (PDX) is an inhibitor of dihydrofolate reductase that was rationally designed to improve cellular uptake and retention of the drug. Preclinical data have shown synergy with the sequential administration of a dihydrofolate reductase inhib
Autor:
S.M. Hussain, Chandrakanth Are, Jean L. Grem, S. Chen, Aaron R. Sasson, Audrey J. Lazenby, James K. Schwarz, Chi Lin, Mary E. Kos, Quan P. Ly
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 84:S320-S321
Autor:
Jean L. Grem, Aaron R. Sasson, Chandrakanth Are, S. Chen, Quan P. Ly, Chi Lin, Mary E. Kos, James K. Schwarz, E.D. Sehi, Charles A. Enke
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 81:S68